中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2010年
4期
16-18
,共3页
王小红%沈云志%范辉%魏荣龙
王小紅%瀋雲誌%範輝%魏榮龍
왕소홍%침운지%범휘%위영룡
胰腺炎%内皮缩血管肽类%巴曲酶%依前列醇%血栓素A_2
胰腺炎%內皮縮血管肽類%巴麯酶%依前列醇%血栓素A_2
이선염%내피축혈관태류%파곡매%의전렬순%혈전소A_2
Pancreatitis%Endothelins%Batroxobin%Epoprostenol%Thromboxane A_2
目的 观察巴曲酶对改善重症急性胰腺炎(SAP)微循环障碍的作用.方法 将38例SAP患者按照平行对照设计原理随机分为A组(21例)和B组(17例),同时以健康志愿者18例作为对照组.A组采用常规治疗,B组采用常规治疗+巴曲酶治疗,以放射免疫法测定血浆内皮素(ET)、血栓素B_2(TXB_2)、6-酮-前列腺素F_(1α)(6-keto-PGF_(1α))浓度及TXB_2/6-keto-PGF_(1α)测定A、B两组胰腺Bahhazar CT分级评分及急性生理和慢性健康状况(APACHE)Ⅱ评分.结果 血浆6-keto-PGF_(1α)浓度,B组入院第6天[(129.3±12.9)ng/L]与入院时[(98.9±10.7)ng/L]及A组入院第6天[(108.2±11.6)ng/L]比较,均显著上升(P<0.05),而血浆ET、TXB_2浓度及TXB_2/6-keto-PGF_(1α),B组入院第6天[分别为(93.8±9.9)ng/L、(254.4±24.9)ng/L、1.83±0.31]与入院时[分别为(140.3±13.1)ng/L、(311.4±31.5)ng/L、3.16±0.54]及A组入院第6天[分别为(120.3±11.4)ng/L、(308.5±31.1)ng/L、2.84±0.43]比较,均显著下降(P<0.05).胰腺BalthazarCT分级评分和APACHE Ⅱ评分,B组入院第6天与入院时及A组入院第6天比较,均显著降低(P<0.05或<0.01).结论 巴曲酶能较好地改善SAP微循环障碍.
目的 觀察巴麯酶對改善重癥急性胰腺炎(SAP)微循環障礙的作用.方法 將38例SAP患者按照平行對照設計原理隨機分為A組(21例)和B組(17例),同時以健康誌願者18例作為對照組.A組採用常規治療,B組採用常規治療+巴麯酶治療,以放射免疫法測定血漿內皮素(ET)、血栓素B_2(TXB_2)、6-酮-前列腺素F_(1α)(6-keto-PGF_(1α))濃度及TXB_2/6-keto-PGF_(1α)測定A、B兩組胰腺Bahhazar CT分級評分及急性生理和慢性健康狀況(APACHE)Ⅱ評分.結果 血漿6-keto-PGF_(1α)濃度,B組入院第6天[(129.3±12.9)ng/L]與入院時[(98.9±10.7)ng/L]及A組入院第6天[(108.2±11.6)ng/L]比較,均顯著上升(P<0.05),而血漿ET、TXB_2濃度及TXB_2/6-keto-PGF_(1α),B組入院第6天[分彆為(93.8±9.9)ng/L、(254.4±24.9)ng/L、1.83±0.31]與入院時[分彆為(140.3±13.1)ng/L、(311.4±31.5)ng/L、3.16±0.54]及A組入院第6天[分彆為(120.3±11.4)ng/L、(308.5±31.1)ng/L、2.84±0.43]比較,均顯著下降(P<0.05).胰腺BalthazarCT分級評分和APACHE Ⅱ評分,B組入院第6天與入院時及A組入院第6天比較,均顯著降低(P<0.05或<0.01).結論 巴麯酶能較好地改善SAP微循環障礙.
목적 관찰파곡매대개선중증급성이선염(SAP)미순배장애적작용.방법 장38례SAP환자안조평행대조설계원리수궤분위A조(21례)화B조(17례),동시이건강지원자18례작위대조조.A조채용상규치료,B조채용상규치료+파곡매치료,이방사면역법측정혈장내피소(ET)、혈전소B_2(TXB_2)、6-동-전렬선소F_(1α)(6-keto-PGF_(1α))농도급TXB_2/6-keto-PGF_(1α)측정A、B량조이선Bahhazar CT분급평분급급성생리화만성건강상황(APACHE)Ⅱ평분.결과 혈장6-keto-PGF_(1α)농도,B조입원제6천[(129.3±12.9)ng/L]여입원시[(98.9±10.7)ng/L]급A조입원제6천[(108.2±11.6)ng/L]비교,균현저상승(P<0.05),이혈장ET、TXB_2농도급TXB_2/6-keto-PGF_(1α),B조입원제6천[분별위(93.8±9.9)ng/L、(254.4±24.9)ng/L、1.83±0.31]여입원시[분별위(140.3±13.1)ng/L、(311.4±31.5)ng/L、3.16±0.54]급A조입원제6천[분별위(120.3±11.4)ng/L、(308.5±31.1)ng/L、2.84±0.43]비교,균현저하강(P<0.05).이선BalthazarCT분급평분화APACHE Ⅱ평분,B조입원제6천여입원시급A조입원제6천비교,균현저강저(P<0.05혹<0.01).결론 파곡매능교호지개선SAP미순배장애.
Objective To explore the effects of batroxobin on the microcirculation of patients with severe acute pancreatitis (SAP). Methods A total of 38 patients with SAP were randomly divided into group A (21 cases) and group B (17 cases). Patients in group A were treated with routine method andpatients in greup B were treated with routine method plus batroxobin injection. Another 18 normal individuals were used as control. The levels of plasma endothelin (ET), thromboxane B_2 (TXB_2) and 6-keto-PGF_(1α)were measured by radioimmunoassay. At the same time, the ratio of TXB_2/6-keto-PGF_(1α) was observed. The Balthazar CT and APACHE Ⅱ scores were monitored and compared between group A and group B. Results The levels of plasma 6-keto-PGF_(1α) were significantly higher while the levels of plasma ET, TXB_2 and the ratio of TXB_2/6-keto-PGF_(1α) were significantly lower in group B at 6 days after admission [(129.3 ± 12.9) ng/L, (93.8 ± 9.9) ng/L, (254.4 ± 24.9) ng/L and 1.83 ± 0.31]as compared with those in group B on admission [(98.9 ± 10.7) ng/L, (140.3 ± 13.1) ng/L, (311.4 ± 31.5) ng/L and 3.16 ± 0.54]and group A at 6 days after admission [(108.2 ± 11.6) ng/L, (120.3 ± 11.4) ng/L, (308.5 ± 31.1) ng/L and 2.84 ± 0.43](P < 0.05). The Balthazar CT and APACHE Ⅱ scores in group B at 6 days after admission were significantly lower than those in group B on admission and group A at 6 days after admission (P< 0.05 or < 0.01). Conclusion Batroxobin is an effective way to improve the microcirculation in SAP.
